Écrit par The Washington Post | 12 Janvier 2015

January 8 at 3:16 PM - A French pharmaceutical company on Thursday said promising results in preliminary research using a combination of existing medications to treat Alzheimer’scould point the way toward someday combating the dementia-causing disease with a drug cocktail.

The drugs, which are not now used to treat Alzheimer’s, include acamprosate calcium, which has been prescribed...

Écrit par Wiley | 12 Janvier 2015

Even decades after being cured, many cancer survivors face physical and mental challenges resulting from their disease and its treatment. That’s the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The findings could help clinicians and other experts develop interventions that are tailored to the specific types of...

Écrit par BONE THERAPEUTICS | 06 Janvier 2015

Gosselies, Belgium, 5 January 2015 - BONE THERAPEUTICS, the regenerative therapy company addressing unmet medical needs in the fields of fracture repair and bone fracture prevention, today announces that it has begun a new research project to investigate novel combined osteoblastic cell-matrix products for the treatment of large bone defects. The government of the Walloon Region has...

Écrit par Lilly | 24 Décembre 2014

Eli Lilly and Company (NYSE: LLY) et Adocia (Euronext Paris: FR0011184241 – ADOC) annoncent aujourd’hui un accord de licence global portant sur le développement d’une insuline ultra-rapide, connue sous le nom de BioChaperone Lispro, pour le traitement des patients atteints de diabète de type 1 et 2. BioChaperone Lispro repose sur la technologie propriétaire d’Adocia BioChaperone et...